Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fcγ-receptors
2001
Neutrophils and Monoclonal Antibodies in Cancer Treatment
publication
Evidence: moderate
Author Information
Author(s): Ottonello L, Epstein A L, Mancini M, Tortolina G, Dapino P, Dallegri F
Primary Institution: Department of Internal Medicine, University of Genova Medical School
Hypothesis
Can chimaeric Lym-1 monoclonal antibody enhance neutrophil-mediated cytolysis in patients treated with G-CSF?
Conclusion
The study found that chLym-1 can significantly enhance neutrophil-mediated cytolysis in patients treated with G-CSF and GM-CSF.
Supporting Evidence
- ChLym-1 triggered low levels of cytolysis by normal neutrophils.
- Neutrophils from G-CSF-treated patients showed consistent cytolysis.
- GM-CSF exposure led to 75% lysis in neutrophils from G-CSF-treated subjects.
- Inhibition of normal neutrophils was observed with specific mAbs.
- Neutrophils from G-CSF-treated patients were inhibited by a combination of mAbs.
- Anti-FcγRIII mAb enhanced neutrophil cytolytic efficiency.
Takeaway
This study shows that a special antibody can help white blood cells kill cancer cells better when combined with certain treatments.
Methodology
The study examined the cytolytic activity of neutrophils from G-CSF-treated patients in response to chLym-1 and cytokines.
Participant Demographics
Patients treated with G-CSF.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website